Disclosures for "Treatments and Outcomes for Patients with Spinal Muscular Atrophy Type 2: Findings from RESTORE Registry ")
-
The institution of Laurent Servais has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Laurent Servais has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. The institution of Laurent Servais has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avexis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dynacure. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Audentes. The institution of Laurent Servais has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Santhera. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RegenexBio. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anagenesis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catabasis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evox. Laurent Servais has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lupin. Laurent Servais has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fibrogen.
-
Kamal Benguerba has received personal compensation for serving as an employee of Novartis Gene Therapies. Kamal Benguerba has stock in Novartis Gene Therapies.
-
Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen and Novartis. Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aspa Therapeutics.
-
Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genethon. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. The institution of Jan Kirschner has received research support from Biogen. The institution of Jan Kirschner has received research support from Novartis. The institution of Jan Kirschner has received research support from Roche.
-
Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sarepta. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Avexis. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Muntoni has received research support from European Commission. The institution of Dr. Muntoni has received research support from Medical Research Council. The institution of Dr. Muntoni has received research support from Biogen. The institution of Dr. Muntoni has received research support from Muscular Dystrophy UK. The institution of Dr. Muntoni has received research support from MDA USA. The institution of Dr. Muntoni has received research support from Sarepta. The institution of Dr. Muntoni has received research support from Association Francoise Myopathies. Dr. Muntoni has received personal compensation in the range of $0-$499 for serving as a Clinical expert with UK NICE Committee.
-
Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avexis. Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sarepta. Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Avexis. Dr. Proud has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Proud has received research support from Biogen. The institution of Dr. Proud has received research support from Sarepta. The institution of Dr. Proud has received research support from Avexis. The institution of Dr. Proud has received research support from PTC. The institution of Dr. Proud has received research support from CSL Behring. The institution of Dr. Proud has received research support from Scholar Rock. The institution of Dr. Proud has received research support from Catabasis.
-
Eduardo Tizzano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Eduardo Tizzano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avexis Novartis.
-
Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis GT. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SAnofi Genzyme. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AVEXIS. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS GT. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis GT. Prof. Quijano-Roy has received publishing royalties from a publication relating to health care.
-
Prof. Desguerre has nothing to disclose.
-
Kyoko Saito has nothing to disclose.
-
Dr. Raju has nothing to disclose.
-
Ms. LaMarca has received personal compensation for serving as an employee of Novartis Gene Therapies.
-
Dr. Sun has nothing to disclose.
-
Dr. Anderson has nothing to disclose.
-
Mr. Faulkner has received personal compensation for serving as an employee of Novartis Gene Therapies.
-
Dr. Finkel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Dr. Finkel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catabasis. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Capricor. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReveraGen. Dr. Finkel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Finkel has received research support from AveXis. The institution of Dr. Finkel has received research support from Biogen. The institution of Dr. Finkel has received research support from Capricor. The institution of Dr. Finkel has received research support from Catabasis. The institution of Dr. Finkel has received research support from ReveraGen. The institution of Dr. Finkel has received research support from Roche. The institution of Dr. Finkel has received research support from Scholar Rock. Dr. Finkel has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Finkel has received intellectual property interests from a discovery or technology relating to health care. Dr. Finkel has received personal compensation in the range of $0-$499 for serving as a Speaker in workshop with National Academy of Sciences. Dr. Finkel has a non-compensated relationship as a advisor with n-Lorem Foundation that is relevant to AAN interests or activities. Dr. Finkel has a non-compensated relationship as a Board Member with EveryLife Foundation that is relevant to AAN interests or activities.